Isotechnika Announces Agreement From the FDA on a Special Protocol Assessment … – MarketWatch (press release)
Isotechnika Announces Agreement From the FDA on a Special Protocol Assessment …MarketWatch (press release)Both phase 3 trials will aim to demonstrate non-inferiority in an efficacy endpoint, primarily driven by biopsy proven acute rejection, or BPAR,…
